125 related articles for article (PubMed ID: 26603680)
1. Serelaxin and acute heart failure.
Tietjens J; Teerlink JR
Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
[TBL] [Abstract][Full Text] [Related]
2. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.
Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR
Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454
[TBL] [Abstract][Full Text] [Related]
3. Relaxin: review of biology and potential role in treating heart failure.
Teichman SL; Unemori E; Teerlink JR; Cotter G; Metra M
Curr Heart Fail Rep; 2010 Jun; 7(2):75-82. PubMed ID: 20424993
[TBL] [Abstract][Full Text] [Related]
4. Role of Vasodilator Therapy in Acute Heart Failure.
Batool A; Salehi N; Chaudhry S; Cross M; Malkawi A; Siraj A
Cureus; 2021 Aug; 13(8):e17126. PubMed ID: 34532168
[TBL] [Abstract][Full Text] [Related]
5. Why Are Physicians So Confused about Acute Heart Failure?
Finucane TE
N Engl J Med; 2019 Dec; 381(24):2375. PubMed ID: 31826354
[No Abstract] [Full Text] [Related]
6. Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.
Feijóo-Bandín S; Aragón-Herrera A; Rodríguez-Penas D; Portolés M; Roselló-Lletí E; Rivera M; González-Juanatey JR; Lago F
Front Physiol; 2017; 8():599. PubMed ID: 28868039
[TBL] [Abstract][Full Text] [Related]
7. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
[TBL] [Abstract][Full Text] [Related]
8. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
[TBL] [Abstract][Full Text] [Related]
9. Serelaxin: A Novel Therapeutic for Vascular Diseases.
Leo CH; Jelinic M; Ng HH; Tare M; Parry LJ
Trends Pharmacol Sci; 2016 Jun; 37(6):498-507. PubMed ID: 27130518
[TBL] [Abstract][Full Text] [Related]
10. Serelaxin for the treatment of heart failure.
Moin DS; Bloom MW; Papadimitriou L; Butler J
Expert Rev Cardiovasc Ther; 2016 Jun; 14(6):667-75. PubMed ID: 27045761
[TBL] [Abstract][Full Text] [Related]
11. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
[TBL] [Abstract][Full Text] [Related]
12. The actions of relaxin on the human cardiovascular system.
Sarwar M; Du XJ; Dschietzig TB; Summers RJ
Br J Pharmacol; 2017 May; 174(10):933-949. PubMed ID: 27239943
[TBL] [Abstract][Full Text] [Related]
13. Contemporary Treatment of Acute Heart Failure.
Hsiao R; Greenberg B
Prog Cardiovasc Dis; 2016; 58(4):367-78. PubMed ID: 26764279
[TBL] [Abstract][Full Text] [Related]
14. Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype?
Hanigan S; DiDomenico RJ
J Pharm Pract; 2016 Feb; 29(1):46-57. PubMed ID: 26759311
[TBL] [Abstract][Full Text] [Related]
15. Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin).
Leo CH; Jelinic M; Ng HH; Tare M; Parry LJ
Br J Pharmacol; 2016 Mar; 173(6):1005-17. PubMed ID: 26660642
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
[TBL] [Abstract][Full Text] [Related]
17. What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?
Cannon JA; McKean AR; Jhund PS; McMurray JJ
Open Heart; 2015; 2(1):e000283. PubMed ID: 26719808
[TBL] [Abstract][Full Text] [Related]
18. Antifibrotic Actions of Serelaxin - New Roles for an Old Player.
Samuel CS; Summers RJ; Hewitson TD
Trends Pharmacol Sci; 2016 Jun; 37(6):485-497. PubMed ID: 26996448
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapies for Heart Failure - Where Do They Stand?
Greenberg B
Circ J; 2016 Aug; 80(9):1882-91. PubMed ID: 27545139
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
